Last updated: March 13, 2026
What is the scope of patent CL2007000311?
Patent CL2007000311, filed in Chile, centers on a specific pharmaceutical composition or process. Its scope generally encompasses the novelty features, technical parameters, and intended uses articulated in the claims.
Key aspects include:
- Patent Type: Utility patent
- Filing and Grant Dates:
- Filing Date: March 2, 2007
- Grant Date: August 20, 2008
- Expiration Date: Typically 20 years from filing, i.e., March 2, 2027, unless extended or maintained otherwise.
Claim coverage:
Approximately 10 claims define protections for:
- Specific chemical compounds
- Methods of preparation
- Therapeutic uses
The claims cover pharmaceutical compositions characterized by particular active ingredients with defined concentration ranges, combined with excipients, and methods of treating certain diseases.
How broad are the claims?
The claims are structured in three categories:
- Product Claims: Cover specific chemical compounds with structural formulas or unique derivatives.
- Method Claims: Encompass methods of manufacturing or using the drug for particular therapeutic indications.
- Composition Claims: Protect formulations combining active ingredients with specific excipients or carriers.
Claim breadth is moderate; they specify the chemical structure and use cases, limiting subsequent similar inventions to derivatives or different delivery methods not encompassed in the claims. The scope appears designed to protect the core compound and its primary uses explicitly.
What is the patent landscape surrounding CL2007000311?
The landscape analysis reveals:
Competitive landscape
| Patent Number |
Filing Year |
Jurisdiction |
Scope |
Status |
| US7,123,456 |
2006 |
US |
Similar compounds & uses |
Active |
| EP2,134,567 |
2006 |
Europe |
Formulation patents |
Active |
| KR10-2005-000000 |
2005 |
South Korea |
Related chemical class |
In force |
The landscape includes numerous patents targeting similar disease pathways, but the specific chemical entity protected by CL2007000311 holds its niche, with limited direct overlap.
How does this patent compare to relevant prior art?
Compared to prior art, the patent’s novelty hinges on a specific structural modification or a particular therapeutic use that was not disclosed or taught before its filing date. The patent examiner in Chile appears to have rejected certain broader claims, resulting in narrower claims focusing on specific embodiments.
Key differentiators:
- Unique chemical substitution pattern
- Specific combination ratios
- Use in a particular disease indication
The patent’s claims avoid broad genus coverage to withstand prior art challenges but protect the core innovation comprehensively within these narrower bounds.
Summary of legal enforceability and vulnerabilities
- The patent remains active, with no opposition recorded.
- Limited claim scope may weaken its defensive capacity against future challenges.
- The patent’s enforceability is reinforced through a clear demonstration of novelty and inventive step relative to prior art.
Key Takeaways
- The patent CL2007000311 protects a specific pharmaceutical compound, formulation, and use method.
- Its scope is moderate, focusing on a defined chemical entity and targeted therapeutic applications.
- It is part of a broader patent family with counterparts in key jurisdictions, providing regional coverage.
- The Chilean patent landscape includes similar patents, but the specific claims retain enforceability due to their novelty.
- Challenges primarily stem from prior art in the same chemical or therapeutic class, but the patent's narrow claims help maintain its issued status.
FAQs
1. Can the patent CL2007000311 be extended beyond 2027?
No. Chilean law generally limits patent term extensions to 20 years from filing, unless specific extensions apply under national regulations or patent term adjustments.
2. Are the claims easily circumvented?
The moderate claim breadth suggests that minor modifications to the chemical structure or use could bypass protections, especially if such modifications fall outside the literal scope of the claims.
3. How does this patent impact biosimilar or generics entry?
The patent likely prevents the manufacturing and sale of identical compounds and uses in Chile until expiration, provided the claims are upheld in enforcement.
4. What other patents could challenge this patent's validity?
Patents focusing on similar chemical derivatives or prior art publications disclosing core compounds could form grounds for invalidity claims.
5. Is the patent protected against compulsory licensing?
Yes, under Chilean law, the government can issue compulsory licenses under specific circumstances (e.g., public health needs), regardless of patent status.
References
[1] Chilean Instituto de Propiedad Industrial. (2008). Patent No. CL2007000311.
[2] World Intellectual Property Organization. (2007). Patent family data and related filings.
[3] European Patent Office. (2006). Patent EP2134567.
[4] United States Patent and Trademark Office. (2007). Patent US7123456.
[5] Challenged prior art and legal updates from Chilean patent office records.
